Amrize's 2027 Outlook Seen Improving After Weak 2026, UBS Says

MT Newswires Live
09/23

Amrize's (AMRZ) 2027 period should be better than 2026, with earnings growth returning to its mid-term target range for the first time in three years, UBS Securities said in a Tuesday note.

Adjusted earnings before interest, taxes, depreciation, and amortization in 2026 are likely to be at par with 2024 levels and "far" from the company's target of an 8% to 11% growth per annum, the brokerage said.

The investment firm cut its fiscal 2026 to 2028 adjusted EPS estimates by 4% to 5% following its reviews of data-center construction and US cement, leaving its forecasts roughly in line with consensus.

According to UBS, Amrize's adjusted EBITDA could increase by 9% in 2027, with demand tailwinds partly offsetting expected import pressures. The company's building envelope segment is poised for mid-teens growth, while the building materials segment is estimated to grow 7%.

Data center construction should also add up to 200 basis points to Amrize's 2027 volume growth, according to the note.

UBS reiterated its neutral rating on Amrize and cut its price target to $42 from $57.

Price: 38.64, Change: +0.05, Percent Change: +0.13

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10